Conkwest is a clinical-stage immuno-oncology company developing cell-based cancer therapeutics with its proprietary Neukoplast® platform. Neukoplast cells possess distinct advantages over garden variety natural killer (NK) cells, which serve to eliminate cancers and virally infected cells from the body. Safety as well as activity against a broad range of cancers have been demonstrated in multiple Phase I clinical trials. Among Neukoplast's attributes is its capability to be administed “off-the-shelf” to patients without need for individualized matching or processing. Moreover, Neukoplast has been bioengineered with enhancements such as CARs and antibody receptors to further optimize targeting and potency against both solid and hematologic malignancies.